A Phase III Study of Safety and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines
Clinical trial NCT03580369 · COMPLETED
Trial details
- NCT number
- NCT03580369
- Sponsor
- Novartis Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2018-10-17
- Primary completion
- 2021-07-16
- Enrollment
- 1072
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.